Skip to main content

Niemann-Pick Disease clinical trials at UCSF

6 in progress, 0 open to eligible people

Showing trials for
  • Early Access Program With Arimoclomol in US Patients With NPC

    Sorry, not accepting new patients

    NPC is a rare, relentlessly progressive, neurological disease and associated with serious morbidity and shortened life expectancy. The purpose of this Expanded Access Program is to provide early access to arimoclomol for patients with Niemann-Pick Type C disease who, in the opinion and the clinical judgement of the treating physician, may benefit from treatment with arimoclomol. Participants will receive treatment with arimoclomol until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason.

    Oakland, California and other locations

  • Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

    Sorry, in progress, not accepting new patients

    Due to different study designs, the sponsor separated Part C into this separate registration (NCT number to be assigned), leaving Parts A/B in NCT02534844. The trial's final results for the primary outcome measure of Adverse Events will be reported here. The primary and study completion dates are based on the anticipated last date safety data will be collected from Part C participants. This study is to find out how safe and effective adrabetadex is for patients with Niemann-Pick Type C1 (NPC1) disease who have neurologic symptoms (listed under Keywords). In Parts A/B (NCT02534844), two out of every three patients will receive the study drug. The third patient will receive 1 to 2 small needle pricks at the location where the IT injection is normally made (sham control). In Part C, all participants will receive study drug.

    San Francisco, California and other locations

  • Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C

    Sorry, in progress, not accepting new patients

    A prospective, randomised, double-blind, placebo controlled therapeutic study in patients with confirmed diagnosis of NiemannPick disease type C (NPC). The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the patient's current prescribed best standard of care; patient's standard of care may, or may not, include miglustat. The CT-ORZY-NPC-002 study has been expanded to include an open label paediatric sub-study including patients aged 6 to <24 months at study enrolment.

    Oakland, California and other locations

  • Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C

    Sorry, in progress, not accepting new patients

    The purpose of this study is to provide continued access to treatment for NPC-1 after participation and completion of the Phase I trial CTD-TCNPC-101, when administered at doses of 1500 mg/kg and 2500 mg/kg by slow IV infusion over a period of 8 to 9 hours every two weeks.

    Oakland, California

  • Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

    Sorry, not currently recruiting here

    A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann Pick disease type C1 (NPC1). The objective of this study is to evaluate the safety, tolerability and efficacy of 2000 mg/kg dose of Trappsol Cyclo (hydroxypropyl betacyclodextrin) administered intravenously compared to standard of care. An open-label sub-study in countries following European Medicines Agency (EMA) guidance will enroll asymptomatic or symptomatic patients from infancy up to age 3 to evaluate safety in that population.

    Oakland, California and other locations

  • VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

    Sorry, in progress, not accepting new patients

    Due to different study designs, the sponsor separated Part C into a separate registration (NCT04958642), leaving Parts A/B here in NCT02534844. This study is to find out how safe and effective VTS-270 is for patients with Niemann-Pick Type C1 (NPC1) disease who have neurologic symptoms (listed under Keywords). In Parts A/B, two out of every three patients will receive the study drug. The third patient will receive 1 to 2 small needle pricks at the location where the LP and IT injection is normally made (sham control). In Part C, all participants will receive study drug, as described in the Part C registration record. Start date for this record is the first day a participant was enrolled in Parts A/B. The trial is actually continuing until the last primary outcome measure of safety data are collected from Part C participants. The last primary outcome measure of safety, along with final adverse events results will be posted in the separate Part C registration record.

    San Francisco, California and other locations

Last updated: